The successful use of pamidronate in an 11-year-old girl with complex regional pain syndrome: response to treatment demonstrated by serial peripheral quantitative computerised tomographic scans.
Complex regional pain syndrome (CRPS) is a disorder that can cause significant functional morbidity. While it usually presents in adulthood, it has also been reported in children. Multiple treatment modalities have been reported with mixed success. Bisphosphonate therapy has been shown to be effective in adult patients, but there are limited data in children. We report the successful use of intravenous pamidronate therapy in diminishing pain, improving function, and restoring bone mass in an 11-year-old girl with CRPS of her left lower limb following a tibial fracture. Previous treatment with intense physiotherapy and regional sympathetic blockade had not improved her symptoms. Pain improved within weeks of the first pamidronate infusion, with subsequent improvement in function. The benefit in pain reduction and function was sustained during the 2-year treatment regime. Improvement in bone mass and density was demonstrated by dual-energy X-ray absorptiometry (DXA) and peripheral quantitative computerised tomography (pQCT). pQCT scans showed marked improvement in bone size and geometry and muscle bulk on the affected side. No adverse affects were reported. We conclude that intravenous pamidronate was associated with reduced pain, a return of function, and recovery of bone and muscle parameters in a child with CRPS. Before definitive conclusions can be drawn, a randomised controlled trial similar to those undertaken in adults previously is required to fully validate this approach.
Simm
P J
PJ
Bone and Mineral Medicine, Department of Endocrinology and Diabetes, Children's Hospital at Westmead, Hawkesbury Rd, Westmead NSW 2145, Australia. peters1@chw.edu.au
Briody
J
J
McQuade
M
M
Munns
C F
CF
D015502:Absorptiometry, Photon; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D015519:Bone Density / Q000187:drug effects*; D002648:Child; D004164:Diphosphonates / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D007866:Leg / Q000503:physiopathology; D000077268:Pamidronate; D012019:Reflex Sympathetic Dystrophy / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology; D013977:Tibia / Q000187:drug effects* / Q000503:physiopathology; D013978:Tibial Fractures / Q000150:complications* / Q000503:physiopathology; D016896:Treatment Outcome
D000893:Anti-Inflammatory Agents; D004164:Diphosphonates; D000077268:Pamidronate